Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH.

While the small sample size of patients with noninvasive test scores in this study means that the data should be interpreted with caution, there was a clear trend between a high-cost burden and worsening scores such as FIB-4, which builds on evidence of increased FIB-4 scores correlating with a higher cost burden. 9 Proactive intervention(s) to delay, halt, or revert the progression of MASH and associated comorbidities could reduce the clinical and economic burden associated with MASH.

also in 19,460 other papers